ArticleBMJ open2026
Nucleos(t)ide analogue therapy combined with pegylated interferon α-2b guided by the GOLDEN prediction model for functional cure of chronic hepatitis B: study protocol (GIFT project).
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe limited efficacy and tolerability of interferon (IFN)-based therapies make refining patient selection a critical step towards achieving a functional cure in chronic hepatitis B (CHB). The novel GOLDEN model, based on sequential changes in quantitative HBsAg (qHBsAg), accurately predicts hepatitis B surface antigen (HBsAg) loss in patients with CHB receiving nucleos(t)ide analogue (NA) therapy. However, it remains unvalidated in patients receiving sequential pegylated IFN α-2b (Peg-IFN α-2b)-based therapy. We aim to validate the GOLDEN model and the optimised cut-off value for the predictive index (Pi) to prospectively identify optimal candidates for clinical cure among patients receiving sequential Peg-IFN α-2b therapy using pre-IFN treatment qHBsAg kinetics across multiple centres. METHODS AND ANALYSIS: This prospective multicentre observational cohort study will enrol 300 NA-experienced patients with CHB from 22 centres in China. Patients, stratified by the Pi calculated from pre-treatment qHBsAg dynamics, will be classified into two groups: favourable (Pi>0.15, n=150) and unfavourable candidates (Pi≤0.15, n=150). All patients will receive 48 weeks of combination therapy with Peg-IFN α-2b plus ongoing NAs. The primary endpoint is the HBsAg clearance rate at week 48, with clearance defined as HBsAg loss at any time during the treatment period. Secondary endpoints include HBsAg seroconversion and sustained clearance rates. The sample size provides 80% power to detect a significant difference between the assumed clearance rates (35% vs 20%, favourable vs unfavourable group). Between-group comparisons will be performed using the χ ETHICS AND DISSEMINATION: The study protocol has been reviewed, and ethical approval has been obtained from the ethics committee of Tangdu Hospital, Fourth Military Medical University (approval no. K202509-69). Approval has also been secured from 21 additional participating centres. TRIAL REGISTRATION NUMBER: ChiCTR2500095819.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.